SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " treat " 2,720 found 🔀 AI-powered Shuffle
New CKM guideline urges early weight talks to prevent health risks
Talk about healthy weight now to prevent serious heart, kidney and metabolic problems later, new treatment guideline says. #CKMsyndrome
In-Room Entertainment Influences Guest Decisions
Hotels that continue to treat in-room entertainment as a cost to be minimized are ceding ground to competitors.
The first-ever reverse-aging treatment has been injected into a human
Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now being tested in humans.
From early lab research to clinical treatments
Studies in mice can be helpful and important. They can point scientists toward new ideas. But they do not guarantee that the same thing will work in
More Americans survive cancer. But the psychological impacts can persist for years
Due to advancements in treatment and screening, more Americans are surviving cancer. But many are left with lingering mental health challenges like anxiety and depression.
NC expands specialized mental health supervision to all 100 counties
Specialty Mental Health Supervision program uses specially trained officers to help people with serious mental illness access treatment and reduce justice system involvement.
FDA approves new inhalable insulin treatment for kids with Type 1 diabetes
Stitch Fix and AMC Entertainment Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the consumer discretionary sector recovered alongside a broad market rebound, helped by easing geopolitical risk and a retreat in Treasury yields from the levels that triggered the previous week's selloff.
United Parks & Resorts and Flutter Entertainment Shares Skyrocket, What You Need To Know
A number of stocks jumped in the morning session after the consumer discretionary sector recovered alongside a broad market rebound, helped by easing geopolitical risk and a retreat in Treasury yields from the levels that triggered the previous week's selloff.
Star Trek star's family awarded $13M in heart failure malpractice case
Nichelle Nichols, who played Lt. Uhura in Star Trek, died from undiagnosed and untreated heart failure after seeking medical treatment.
We can create the future of science right now
Paul Litvak is the founder and Executive Director of the Robyn Dawes Institute and a Visiting Scholar at UC Berkeley. He has a PhD in Behavioral Decision Research from Carnegie Mellon where he studied emotions and the sunk cost bias. Over 15 years in industry, he solved a wide range of challenging technical problems. At Meta he created models optimizing the ad review process. At Google he ran experiments to measure social influence. At Airbnb, he was a product manager leading machine learning teams optimizing search ranking and price suggestions. He also co-founded and led product at Rhythmic Health, a venture-backed biosensing startup, creating an accurate low cost system using a color changing strip and a smart phone to measure salivary lactate. The bottleneck At this point, it is uncontroversial to say that science needs to stop using the PDF article as the unit of knowledge and currency. The unbearable slowness of scientific publishing, the profit motive and margins: I’m not saying anything new. The PDF also sucks because it’s hard to extract structured information, which makes it hard to do evidence synthesis. As a result, we do much less evidence synthesis than is needed. And evidence synthesis ultimately undergirds most policy and medical decision-making. I can see second-by-second real-time odds for any sporting or newsworthy event, but a school board can’t see the best evidence on whether their 8th graders should be taught algebra. As a society, we don’t treat this as an important problem. Again, not controversial. Not only is the problem well understood, but the solution has already been laid out. What we need is AI-assisted living evidence synthesis - (1) an open knowledge graph of atomic claims, (2) claims linked to evidence, (3) assessment and synthesis of each piece of evidence, and (4) continuous updating with new data. What few realize (yet) is that the technical capacity to build this vision for a significant portion of science already exists. Not only that, scientists and startup teams are already building many of these components. I know this because I’ve been surveying the space and talking to many of the builders. There are some missing pieces: for example, evaluations of how well some of the components work. But at this point, most of what’s missing is a fully end-to-end working integration of all of these parts. In the rest of this essay, I’m going to lay out all the parts of a working living evidence layer for science and who is working on them, and propose concrete next steps for building this system. What’s now possible The diagram above outlines the components of a living evidence synthesis platform, including some of the teams working on each component1. Scientific PDFs are processed into claims with associated evidence. The evidence is subjected to a forensic audit, methodological evaluation and robustness and reproducibility checks. Finally it’s given a weight in a continuously updating synthesis. What follows is a description and status of each component and a few of the teams working on them. Document understanding The first thing you need to be able to do is turn an article into structured data. Mostly that means parsing PDFs. There are often multicolumn layouts that confuse non-specialized PDF to text processing libraries. For scientific papers, there is the added complexity of parsing formulas and tables and figures. This is a really hot area - there are startups offering APIs, and it seems like a new open source package gets posted to Github every few weeks. What follows isn’t exhaustive. A package called GROBID was the state of the art for a while, they didn’t update their package for nearly two years until very recently. In the meantime reducto.ai released an AI powered PDF extraction API, PaddleOCR became popular, IBM released a model called Docling, and both Mistral and Gemini created models and libraries. I also know of at least one other well-funded psychology research group working on a paper parser. By contrast, there are few open evals in this space, with no extensive evals for complex table comprehension in particular. Nonetheless, I’m confident this will be a solved problem soon, given the combination of LLM advances and developer interest. Hypothesis level extraction There has been increasing interest in comprehending the extracted text of papers and linking information to evidence for each hypothesis. A lot of work has already been done. Trialstreamer (Marshall et al. 2020) and RobotReviewer LIVE (Marshall et al. 2023) demonstrated automated extraction of trial population, intervention, and outcome at scale on clinical RCTs. PaperQA2 (Skarlinski et al. 2024) and Ai2 ScholarQA (2024) extended this to retrieval-augmented question answering with citation grounding. Elicit, Consensus, and SciSpace operationalized claim-level extraction for end users. OpenEval (Booeshaghi et al. 2026) is the most recent and most ambitious: 1.96 million atomic claims extracted from 16,087 eLife manuscripts using Claude Sonnet 4.5, grouped into ~299,000 results, with LLM evaluations showing 81% agreement with human peer review on a 2,487-paper subset. None of these solutions link claims to test-statistics, as you would need to evaluate randomized controlled trials. This is why I built the evidence.guide API - to extract hypotheses and associated test statistics from behavioral science papers. The best public eval of this kind of extraction I’m aware of comes from the recent SCORE project - they had humans code thousands of psychology papers to extract their claims by hand. It would be extremely helpful to the world if all scientific PDFs were available as structured open data. I’ve been working to make this happen, both directly at Berkeley and through coordination with large entities I can’t yet speak of; as hard as it is to do, I think it’s possible2. Forensic audit A lot of work has been done on forensic audit, but some gaps remain. Of course, for biology papers that rely on images for evidence, there are a variety of tools (notably Proofig and ImageTwin) to spot anomalies. These are still well short of what sleuths like Elizabeth Bik can do on her own, but these tools are constant companions among fraud analysts. There’s someone working on auditing Excel files for anomalies, and a number of teams are automating numerical checks like GRIM and SPRITE, including Scrutiny project, the INSPECT-SR team as well as statcheck. The regcheck team is building a way to use AI to compare preregistrations to analyses in papers, to ensure there aren’t significant deviations. Nonetheless, there are many other kinds of anomalies to screen for, both public and less publicly known. And there are no formal evals for anomaly detection that I’m aware of. Still, there’s a lot to draw from in this space and I’m pretty certain we will be able to scan papers for most kinds of obvious anomalies in the near future. Methodological review This area has been white hot, though I fear for many of the startups in this space, because this capability may become commoditized. There are at least six different AI peer review companies, including Refine.ink, Reviewer3, ReviewerZero.ai, Q.E.D. Science, Paper Wizard, and Isitcredible. Coarse (a pun on refine) was also recently created as an open source alternative. These systems provide qualitative feedback on the content of papers, spotting methodological weaknesses and mathematical errors. They seem to work pretty well, and many academics report bitterly that they exceed the average quality of typical peer reviewers. But there are few evals here either. What evals exist so far involve using LLM-as-judge (circularity problems abound) or comparing against human reviews of questionable quality. What you’d ideally want is an eval that measures capturing known errors in papers3. Reproducibility and robustness Another active area has been using AI agents to automate computational reproducibility4 and robustness5 checks in papers that report numerical results. For more recent papers where data and code are available, AI agents can see whether they can re-run the analyses and produce the numbers reported in the published paper. In addition to a handful of individual academics who have been experimenting using Claude Code for this, the Institute for Replication is a leading group working on building an end to end system. The evals related to this problem are the most mature, with CORE-Bench (Siegel, Kapoor, Narayanan 2024) and PaperBench (OpenAI 2025) available to benchmark agents on this task. There is also work on getting AI agents to test alternative ways of analyzing the data to ensure the results are robust to small analytic design choices. Synthesis This is the most underdeveloped area where significant investment is required. Although some automated evidence synthesis systems exist — for example, otto-sr is building an AI agent to write systematic reviews — none of these incorporate the full range of paper level signals to weight evidence appropriately. Nor is there anything like an eval or a gold standard for a good systematic review. Arguably Cochrane reviews are the closest we have to gold standard human systematic reviews, though I’ve heard academics in the know complain about their uneven quality. A key question for a synthesis platform is how to weight anomalies and methodological issues in assessing the quality of a piece of evidence. This is an unsolved problem and one I’m very keen to work on. Continuous updating There are many pieces of basic infrastructure available for monitoring for new research and initiating updates. OpenAlex is the current open citation graph. Retraction Watch integrated into Crossref in October 2023. Scite tracks how citations support, contrast, or mention prior claims. The Living Evidence Network demonstrated continuous-update workflows in clinical guidelines. Engineering this is a relatively straightforward task. When you look over this technical architecture and all the progress being made, it’s hard not to be optimistic that a living guide to scientific evidence will be built. The stakeholders are ready The social infrastructure for this is starting to coalesce — it’s not just a pie in the sky academic exercise to imagine this coming into existence. Institutions like the Center for Open Science, the Institute for Replication, the INSPECT-SR, the Living Evidence Network and more are all working on scaling work to improve research quality. Funders are also aligned. The Sloan Foundation has funded living evidence work through COS. Coefficient Giving supports the Institute for Replication and COS. The Astera Institute and the Institute for Progress have shown interest in this space. NIH has established an Office for Replication and Reproducibility. Although there are (very unfortunately) serious headwinds in science funding generally, there is an active group of funders interested in metascience. A brief word about what I’ve been doing at RDI. First, as a Visiting Scholar at Berkeley I’ve been actively figuring out how a non-profit and a public university can conduct and make public the results of large-scale academic article data mining. With some of the money I raised from donors, I commissioned a legal analysis of recent case law and publisher text data mining (TDM) agreements in order to understand whether a massive open data mining of academic articles is possible (with caveats, it is). I’ve also been working to bring together stakeholders in this space, and identify gaps. I’ve also been doing some software development in this space, with more to come. A pilot proposal The assumption undergirding all of this is that an AI, given all this information, would make the right judgment about a scientific claim with lots of conflicting evidence, weighing all the factors appropriately. That’s the hypothesis we need to test. Randomized control trial research is the best place to focus on first. RCTs are used to make many of the important decisions in society - from medical trials to public policy changes. And they use a relatively uniform set of inferential statistics with lots of known and available diagnostics. Behavioral science experiments, within the broader realm of RCTs, should be first used as a testbed whose results can be generalized. Because behavioral science is at the vanguard of open science practices, replications abound (there are thousands of them) to serve as ground truth training data. Key Hypothesis Therefore the pilot would test, in behavioral RCTs that have been replicated, whether the quality of evidence for a claim can be used to accurately predict whether that claim will replicate. Secondary Hypotheses Compared to claims that replicated, non-replicated claims demonstrate a greater share of forensic anomalies in their source literatures. Hypothesis level claim and statistic extraction is accurate enough to scale living evidence without onerous human review costs. Replication prediction is more accurate than prediction markets6 or journal prestige. If all the different quality signals we gather do accurately predict which studies will replicate, then we can use that model to score evidence to power the living evidence layer. Why this is informative regardless of outcome If the pilot succeeds, the architecture extends to medical RCTs (where Living Evidence already operates and integration is mostly about claim representation), then to slices of basic biology with stable replication structure. If it fails, the field learns which quality signals are load-bearing and which ones metascience has oversold. Either result is a contribution to knowing what the literature supports. Implications for funders Because this burgeoning ecosystem of builders already exists, a well-informed philanthropic or government funder could play a crucial catalyzing role in bringing this future about. They could play at least three roles: creating open structured datasets, publishing open benchmarks and incentivizing the solving of key technical challenges. First, open archives of papers that the government maintains, like PubMed, could be turned into structured data amenable to large scale metascience and claim aggregation. I know the US government already has an interest in doing this, though some key open questions remain unanswered. How do you determine the best models and systems for accurately extracting information from papers? How can you establish a robust way to allow researchers to flag errors and correct them? And finally, how do you create a legal regime in working with publishers to maximize the scope of available papers? For the latter, a university or a private philanthropy may be better positioned to make structured data publicly available under journal subscription terms or fair use. Philanthropists or government funders could also coordinate to create or commission benchmarks that evaluate whether important problems have been solved. For example, an open benchmark for claim extraction from a range of different scientific article types would be extremely helpful. Ensuring the underlying data are accurate is vital for creating these evaluations. I’ve discussed opportunistically using various human-created datasets for this purpose, but a consistent problem is that errors in human data make it difficult for them to serve as a gold standard. Finally, with structured data and benchmarks available, the government or private philanthropy could use them to incentivize groups to develop machine learning systems that meet these benchmarks. Prizes are one potentially valuable tool for this. For example, you could establish a prize for a system that accurately updates a living meta-analysis for a small set of claims. Prizes are particularly useful as signals of problem importance, and can help create vibrant ecosystems of public and private research—see, for example the role the government played in kickstarting the current work on nuclear fusion. Conclusion The drawbacks of the current scientific publishing system are known. Scientists agree, metascientists agree, philanthropists agree: the published PDF plus citation graph isn’t the right substrate for maintaining a representation of the evidence base in science. The pieces needed to build the alternative either already exist or are rapidly taking shape. The community is forming around exactly this problem, with concrete partnerships and shared infrastructure. A pilot should start on behavioral science RCTs because that’s the slice of empirical science most amenable to legibility, where replication ground truth is richest, and where the failure modes are best documented. What’s been missing is the galvanizing mission to assemble these pieces into something that works. That’s what I’m proposing to build. *** 1 I have a broader field map that I’ll release publicly soon. This is me, building in public! 2 If this is something that you are excited about, please reach out and talk to me. 3 More on this very soon too! 4 This tests whether, given the code and the data, you can get the same statistics as reported in the published paper. 5 This tests whether the results are the same as a paper’s given alternative analytical decisions in conducting the analysis (like outlier omission). Closely related is the idea of a “multiverse” where you come up with many different ways of answering the same underlying research question with the same data, and test whether the results hold in all those alternative methods. There’s been work on the latter as well. 6 Some of the replications, e.g. those from the SCORE project, had paired the experiments with forecasts from prediction markets. So we get to look at this for free.
WAMU's week ahead: D.C. Council tackles a delayed budget, preventing ticks from biting into your summer and the politics of streateries
This week WAMU will be checking in on the D.C. Council's first vote for the FY2027 budget, responses from health officials to increased tick bites across the D.C. region and the politics at play this summer around streateries.
Stitch Fix and AMC Entertainment Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the consumer discretionary sector recovered alongside a broad market rebound, helped by easing geopolitical risk and a retreat in Treasury yields from the levels that triggered the previous week's selloff.The sector was among t…
Understanding anorexia’s grip on the brain could unlock new therapies
One-third of people with anorexia nervosa don’t recover and treatment has remained stagnant for years. Now we’re beginning to understand how the condition takes over the mind
She started a dog treat business while serving in Air Force
An Air Force member has launched a dog treat business connecting her military service with her love of animals.
She started a dog treat business while serving in Air Force
An Air Force member has launched a dog treat business connecting her military service with her love of animals.
She started a dog treat business while serving in Air Force
An Air Force member has launched a dog treat business connecting her military service with her love of animals.
Corporate Support for Pride Makes a Quiet, Cautious Comeback
LGBTQ groups claw back business sponsorships after anti-DEI retreat.
Scientists found a new Alzheimer’s trigger and a drug that stops it
Researchers have identified a new Alzheimer’s target and created an experimental compound that blocks a damaging process inside brain cells. In mice, the treatment slowed nerve cell loss, reduced Alzheimer’s-related changes, and even appeared to promote healthier aging.
Florida earns C- for maternal mental health care
About one in five U.S. moms experience maternity-related mental health conditions like postpartum depression, and most don't get the treatment they need.
GE HealthCare gets FDA OK for radiation treatment AI tool
GE HealthCare is putting its MIM imaging software to work to equip oncologists with more personalized planning advice to maximize, and minimize, radiation treatment.
Summer may ease pressures on youth, but it's a good time to address mental health concerns
Getting teens treatment during the break can set them up for success when school returns and anxiety spikes.
The American Family Is at a Breaking Point. Our Politics Have Finally Noticed.
Society has treated parenting as a private endeavor. But what if raising children is also a public good?
Accelerated PTSD care offers faster relief for veterans
Rush University System for Health’s Road Home Program helps veterans recover with intensive, evidence-based treatment, while preserving their dignity.
Platner holds town hall in Portland as he looks to steady Senate campaign
Graham Platner was met by an enthusiastic and supportive crowd Sunday at a town hall-style event in Maine as the Democrat moves to stabilize his Senate campaign after new reports about his past treatment of women.
Beyond BMI: New Score Stratifies Obesity Risk
BMI, while useful, is insufficient to identify patients at the highest risk for obesity-related complications. A new tool may help clinicians better stratify risk and target treatment.
Stealth classic Thief: The Dark Project is getting the remaster treatment from retro specialist Nightdive Studios
After successfully tackling System Shock and its sequel, retro specialist Nightdive is remastering another classic immersive sim.
The Probiotic Breakthrough for Natural Anxiety Relief and Better Mental Health
A surprising gut-brain discovery suggests that anxiety could one day be treated with specially designed probiotics. Could anxiety be shaped, at least in part, by tiny organisms living in the gut? Research from Duke-NUS Medical School and the National Neuroscience Institute of Singapore points to
Big money is pouring into South Florida health systems. What it means for patients
Big-money donors are pouring millions into South Florida hospitals, reshaping cancer care, research, and treatment options across the region.
Huge Psilocybin Dose Has Incredible Effect on Elderly Dementia Patient
A radical new treatment may be emerging.
Simone Biles Says Medical Scare Was Because of Health, Not Accident
Biles did not elaborate further on what caused the incident or whether it involved ongoing hospital treatment.
Dr. Andrew Parsons: Dr. ChatGPT is getting remarkably good at diagnosing health problems — but actual doctors are still better at weighing treatment options
A father is worried about his toddler, who has been running a fever for two days and pulling at one ear. A 65-year-old woman has been getting winded on her morning walks and feeling more fatigued than usual. Both reach for their phones and type their symptoms into an AI
Inside SHA’s Revolutionary New Women’s Health Retreat
We visit SHA's clinic in Spain to experience its new female-focused pack, where hormones and longevity are approached as one interconnected system.
One UVM lab’s surprise discovery led to flu science breakthrough
Proteins in the two most common types of flu virus enable them to take very different paths to entering human lungs, a finding that could lead to more directed antiviral treatments.
IV therapy could lower the body's microplastics
A treatment embraced by Bryan Johnson and Gwyneth Paltrow is now being studied for its effects on blood microplastics.
AI is getting remarkably good at diagnosing health issues, but doctors are still better at weighing treatment options
Knowing what ails a patient is necessary but not sufficient for determining how to care for them. And how to manage a patient is a complex question.
Ancient Chinese medicine could transform hair loss treatment
A traditional Chinese medicinal root used for over a thousand years is attracting new scientific attention for its potential to combat hair loss. Studies suggest Polygonum multiflorum can block harmful hormones, activate hair-growth signals, protect follicles, and boost blood flow to the scalp. Researchers say the herb’s effects align remarkably well with both ancient descriptions and modern hair biology.
Why is young colon cancer rising? New research shows food, gut health
Young colon cancer may not be not the same disease doctors are used to treating. Researchers are discovering new links to modern diets and gut toxins.
Why is young colon cancer rising? New research shows food, gut health
Young colon cancer may not be not the same disease doctors are used to treating. Researchers are discovering new links to modern diets and gut toxins.
Hosting the World Cup makes US 'really ripe' for diseases, experts worry
The U.S. retreat from the world's public health stage amid disease outbreak has some experts concerned about infectious diseases.
Jill Biden’s book tour reopens wounds, sparks Biden-world infighting
The former first lady’s memoir has made some Democrats frustrated at relitigating the 2024 presidential election and her treatment of a once loyal White House aide.
Scientists sound the alarm as dangerous amoebas spread globally
Scientists warn that free-living amoebae may be an underappreciated public health threat, capable of causing deadly infections and shielding other dangerous microbes from water treatment. Climate change and aging infrastructure could help these resilient organisms spread more widely in the years ahead.
Satya Nadella says AI agents should be treated like human employees
Microsoft CEO Satya Nadella says companies should manage AI agents like employees, giving them identities and permissions.
E-bike safety; lung cancer treatment and prevention; keeping CMA Festival attendees safe; plus other stories with Vanderbilt Health sources
WKRN News 2 interviewed Jeffrey Upperman, MD, FACS, Professor and Chair of the Department of Pediatric Surgery and Surgeon-in-Chief of Monroe Carell Jr. Children’s Hospital at Vanderbilt, about e-bike related injuries following the recent death of a Brentwood High student and a proposal to require safety training before students could ride a bike on a school campus in Williamson County. Fabien Maldonado, MD, MSc,Professor of Medicine and Thoracic Surgery, was on WTVF News Channel 5‘s live studio show, “Openline,” with host Ben Hall, to discuss lung cancer, treatment and prevention. WSMV’s “Today In Nashville” program hosted Vanderbilt LifeFlight paramedic/flight nurse practitioner Tony Smith to talk about safety for the CMA Festival. The New York Times reporter Carl Zimmer interviewed James Crowe, MD, Director of the Vanderbilt Center for Antibody Therapeutics, for a story about the race to find vaccines and treatments as Ebola spreads. The Vanderbilt Health News release about the pilot clinical trial conducted by Vanderbilt Health and Cumberland Pharmaceuticals Inc., that confirms the safety of ifetroban and supports the further development of the drug to prevent cancer metastasis, was picked up by Reuters, Stock Titan,and others. Women We Admire has named Lee Ann Liska, President and Chief Operating Officer, to its list of top women leaders of Nashville for 2026. Radiology Business, Aunt Minnie, Bioengineer, and Imaging Technology News covered the study from Consuelo Wilkins, MD, MSCI, the Mildred Thornton Stahlman Professor in Rural Health and professor of Medicine in the Division of Geriatric Medicine, that found Black and Hispanic people, while known to be far more apt to have dementia, are significantly less apt than other racial and ethnic groups to show Alzheimer’s pathology on brain scans. STAT News interviewed Deva Sharma, MD, Transfusion Medicine & Hematology-Oncology, for a story about more patients requesting unvaccinated blood and what it means for the medical system at large. Yahoo! Health reporter Korin Miller interviewed Gitanjali Srivastava, MD, Director of Obesity Medicine, for a story about how semaglutide and tirzepatide compare. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: NBC News (new COVID vaccinations); Medscape (pneumonia and sepsis); and CNN (protection from contagious viruses). Shelbyville Times-Gazette is repurposing Jessica Pasley’s July 2025 Vanderbilt Health News story on tick-borne illnesses as a front-page story.
Scientists discover why ozempic may not work for some people
Scientists have identified genetic variants that may make some people less responsive to GLP-1 drugs used to treat Type 2 diabetes. Roughly 10% of the population carries these variants, which appear to cause a mysterious form of "GLP-1 resistance." In several clinical trials, carriers were significantly less likely to reach healthy blood sugar targets while taking GLP-1 medications.
Sussex woman says mental health unit left her with trauma and PTSD
Dulcie, 20, supports a new scheme where youngsters in a mental health crisis are treated at home.
How Funding Cuts Left the World Vulnerable to Ebola
A strain with no known treatment or vaccine is spreading fast, and the international system built to contain outbreaks is in crisis.
Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival
For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic tumors—something many scientists once thought couldn't be done. In a major clinical trial, the treatment nearly doubled survival for patients with advanced disease and reduced the risk of death by 60%.
2026 Tax Treaty Survey Highlights U.S. Business Priorities - National Foreign Trade Council
Washington D.C. – The National Foreign Trade Council (NFTC) today released results from its annual Tax Treaty Survey. The survey, which was answered by tax professionals from NFTC member companies, asked businesses to rate their tax treaty priorities around the world. “Tax treaties are essential for U.S. businesses, and we are thankful that Treasury is […]
Opinion | Melinda French Gates: America Needs a Menopause Revolution
Too many women walk out of their doctors’ office with no diagnosis, no treatment and no plan.
Mental Health Courts Offer People Facing Prison an Imperfect Alternative
Hundreds of U.S. courts offer treatment over prison for some defendants with mental illness. But critics say mental health courts have outpaced research on their effectiveness.
Future of mental health treatment, California bank standoff, monkeypox scandal | FOX 10 Talks
Join FOX 10 Anchor Brian Webb and Executive Producer Trenton Hooker for a fast-paced, can’t-miss breakdown of the biggest stories making headlines right now.
An Uncertain Path for Americans Exposed to Ebola
Despite long-established procedures for bringing Americans home for monitoring and treatment, the Trump administration has not said that it will allow those at risk of Ebola back into the country.
Study questions standard screening test for amputation risk in veterans
In a review of the electronic health records of more than 223,000 veterans treated at Veterans Health Administration facilities, the researchers found that even modest decreases in the normal ABI correlated with a higher risk of major adverse limb events (MALE) requiring intervention, including amputation and revascularization (treatment to restore blood flow).
Curbing Congo’s Ebola outbreak is hampered by unknowns about the virus
Answers to key questions could help public health officials develop Ebola treatments, predict the outbreak’s trajectory and prevent a future one.
Keto diet shows real promise for anorexia recovery
Restricting carbohydrates may sound like an unlikely approach to treating anorexia, but following a ketogenic diet was linked to recovery in 3 in 4 people with the eating disorder in a small trial
This new diabetes pill burns fat without the downsides of Ozempic
Scientists have developed an experimental diabetes and obesity pill that works in a completely different way from drugs like Ozempic. Rather than reducing hunger, it activates metabolism in skeletal muscle, helping lower blood sugar and increase fat burning while preserving muscle mass. Early clinical results suggest the treatment is safe and well tolerated.
Scientists reverse anxiety by fixing a tiny brain circuit
A newly identified group of amygdala neurons appears to play a central role in anxiety and social behavior. Restoring normal activity in this tiny brain circuit reversed anxiety and social deficits in mice, revealing a promising new target for future treatments.
The cult of objectivity has broken consciousness science
With 22 competing theories and no consensus in sight, the science of consciousness is lost. In this exclusive IAI interview, Berkeley psychedelics researcher and bestselling author of a new book on consciousness Michael Pollan insists that even though consciousness lies beyond traditional forms of scientific investigation, we should resist becoming dualists who see it as something radically different from ordinary stuff in the world. Instead, he makes the case for reimagining science itself: it must stop reaching for objective descriptions of physical reality, and instead embrace subjectivity as the indispensable core of all inquiry. Alasdair Craig: How did your experiences with psychedelics get you interested in consciousness?Michael Pollan: One of the things that happens on psychedelics is that they foreground consciousness. What formerly seemed perfectly transparent and ever present—and yet, non-existent, as water is to fish—suddenly you see it. The metaphor I use in the book is that psychedelics sponge the windscreen. Suddenly you realize: wow, there’s a windscreen, there is this phenomenon that’s mediating my relationship to reality. This is not an unusual realization on psychedelics. I think a lot of people are called to think about consciousness after psychedelic experiences. So that was the proximate inspiration for A World Appears: A Journey Into Consciousness (2026).And then there was a more specific way in which psychedelics influence the book. That was a particular experience I had on psilocybin. I had the sensation that the plants in my garden were conscious and returning my gaze, with their own point of view and agency, and I got curious as to how to evaluate an insight like that. I mean, what’s the truth quotient of insights you have on psychedelics? And I was reading William James—who, of course, wrote beautifully about mystical experience—and he said, we can’t judge the metaphysics here, but we should pay attention to two criteria: (1) How useful is it to think this is true? He was a pragmatist, of course. And (2) can we subject it to other ways of knowing to validate it? Because maybe we should treat these insights as hypotheses. And that’s kind of how I approach psychedelics, as a great generator of hypotheses, but they need to be tested against other ways of knowing. And so that led me down this long path exploring the science of plant intelligence and plant sentience.AC: I love your phrase, “smudging the windowpane of conscious experience.” So do you now start to think, actually, even when I’m not on psychedelics, I’m just seeing a screen all the time, which is not reality, but rather is my conscious experience, behind which reality is hidden?MP: Well, you know, not when I’m brushing my teeth and making breakfast! But yes, in meditation, certainly. I mean, one of the things you realize is that my experience happens to be this way now, but it could be another way. And many things can affect it. My morning coffee changes the screen in various ways, sharpens certain things.___The only tool we have to understand consciousness is consciousness.___There’s this wonderful metaphor in Aldous Huxley’s book, The Doors of Perception, where he thinks we channel consciousness, and that what the brain does is edit it, and there’s a reducing valve. And psychedelics open the reducing valve wider. I don’t know that I’m ready to buy into the idea that consciousness exists outside brains, but I do love that metaphor because there are times when you are more conscious than others. I know I’ve switched from window pane to valve, but you know, a camera aperture can open wider or narrower. And I do have a sense of that. I have a sense of when I’m being less conscious, and when I’m being more conscious, by which I mean, you know, more present, taking in more sensory information. So when you start thinking about consciousness as a matter of degree, that changes things also.I think when we scroll on social media, obviously, we’re conscious. But minimally so, because we don’t have to generate our own thoughts. We’re basically taking these little hits from other people and thinking their thoughts.The process of writing this book made me kind of relativize everyday consciousness as just one type, which is exactly what William James said. Normal consciousness is one type, separated by the flimsiest of screens from the other types.AC: If we stick with the metaphor of the smudge on the window that you get when you take psychedelics, it seems like we’re saying that consciousness has become like an object that you’re looking at, right? You’re looking at the smudge and that just is consciousness. But sometimes we’ll talk about consciousness as a state that you’re in, rather than an object you can perceive. You’re either conscious or you’re not conscious. So it’s difficult to really know what sort of thing we’re talking about when we talk about consciousness, right?MP: Yeah. When you say that consciousness is an object, what’s the subject? Consciousness also? The only tool we have to understand consciousness is consciousness. So we’re in a closed loop and when we get a perspective on consciousness, we’re not achieving any distance from it. That’s one of the problems with studying consciousness. Science is predicated on an objective, God’s eye view of things, and you never get that. There’s no such thing. SUGGESTED VIEWING The brain filters consciousness With Àlex Gómez-Marín But, yeah, there is this sense, I think, that consciousness is something you can approach. Certainly, when you’re writing and trying to recreate a conscious experience, it’s a fiction, but you’re standing back from it, and looking at it. But there’s no real subject-object distinction.AC: That’s so interesting, because when philosophers start talking about consciousness, they often talk about what they call “qualia”, which is their word for the felt experience of, say, the color red. And I think that way of speaking often makes us think of the qualia as an object, which you can see out there: the redness of red. But, as you say, we also want to collapse the subject-object distinction when we talk about consciousness. So there’s something strange going on here…MP: Oh, yeah, there are many strange things going on! *AC: Let’s talk about the varieties of consciousness. Apart from perceptions, there are, pains, emotions, thoughts, and so on. What is it that holds all this diversity together so that they all count as instances of consciousness? What is it that they all have in common?MP: Yeah, that’s a really good question. I mean, there is sensory information, right? Which we perceive coming from the world outside ourselves. And then there’s internal information, which is what’s called interoception. And this is very important too. This is where feelings come from—what are sometimes called homeostatic feelings—that are intended to get the brain to keep us in these narrow ranges of temperature and glucose and so on. That’s a very important part of consciousness. And according to some researchers, who I think are probably right, this is where consciousness begins, with these very primal feelings, like hunger and thirst and warmth and itch, and things like that. And then there’s this third thing, which is our thinking about thinking.And what holds all this together is, I think, the sense of self. Consciousness generates a self: it is probably an organizing principle. All this stuff is happening to the self. It’s a construct, I think, but it is very useful. It can connect all these different streams of consciousness to a single being or a place, metaphorically speaking.* AC: The first half of your book is about the science of consciousness. Is consciousness just another thing, like black holes or the origin of life, which we don’t yet understand, but which we should have every hope that science will one day get to the bottom of, or is there something special about consciousness that makes this unlikely?MP: It depends how you define science. As we define science now, it’s going be very difficult. Science since Galileo has had a set of rules or assumptions, which is that the proper remit of science is to deal with the objective, quantifiable, third-person world. And the physical sciences have done amazing work under that set of limitations. Galileo—for tactical reasons, not for philosophical reasons—said science should not deal with the soul, which at the time was what consciousness was considered to be. So what is subjective, what is qualitative, what is first person, we’re going to leave to the church, he said. And this was a good agreement, and it probably kept many scientists from getting burned at the stake. But it leaves science in an awkward spot, now that it wants to venture into that territory of qualities, of first-person experience. And I don’t think it has the proper tools. I think it will have to add to its toolkit in some way, and find a way to bring in phenomenology, or lived experience and introspection, which science is usually dismissive of.The challenge—we alluded to it earlier—is that the only tool you have to study consciousness with is consciousness. And what I mean by that is, the whole scientific enterprise is a manifestation of consciousness. As much as scientists like to flatter themselves with this idea that they attain a godlike perspective on what they study, when it comes to consciousness, there’s no such thing. And it’s fine for all the things you can step outside of and study from that perspective. But two areas it won’t work are consciousness and cosmology.___It could be that we live in this anomaly of not believing nature is conscious. And maybe psychedelics are teaching us something we’ve forgotten.___With cosmology, too, you have to study the universe from inside the universe. It’s not that cosmologists haven’t made progress. We know a lot about the age of the universe and expansion and things like that. But we can’t penetrate what happened before the Big Bang. We just don’t have the tools because we can’t stand outside.The fact that there are 22 full-scale theories of consciousness tells you all you need to know: we’re kind of lost. And I was surprised to find that we are more lost than I thought we were when I started this. I thought that there’d be leading theories, or that we had experiments that we could conduct that would nail some of this down. And the fact is, we don’t.So, I don’t know if science can solve it. But, of course, we can change the rules of science. A really influential book for me was a book called The Blind Spot, by two physicists, Marcello Gleiser and Adam Frank, and a philosopher, Evan Thompson. It’s a reminder that science is a social practice. It’s organized in a certain way and it can be organized in a different way. But it has this huge blind spot at the center of it, which is its failure to recognize that it is a form of consciousness itself, and it doesn’t have a good way of taking account of lived experience.AC: On the one hand, I think you want to resist traditional dualism, which would say that consciousness is something magical, something supernatural, right? But on the other hand, you’re accepting that there is this division in reality between the stuff that you can investigate objectively and measure, and so on—the stuff that science has been good at finding out about—and consciousness, which, for some reason, you can’t objectively measure. Some would take this to suggest that the dualism is actually right. Is there a way of reconciling these two strands of your thinking?MP: To call it magical is full of value judgement. I mean, you could just say immaterial. The interesting thing is, I think, that intuitively we’re all dualists. And I don’t know whether that’s because we’re children of Descartes and other cultures are less dualist than we are. Or it may be because that’s how consciousness feels. It feels different than the body. It feels separate from the body. But I don’t think we should trust that intuition.AC: So let’s think about ways that science might be changed to get at consciousness. I suppose the starting point would be the way that you begin the second half of your book. You have this nice line from William James, where he says, “We now begin our study of the mind from within.” Could you give us some sense of the ways of studying the mind from within? What does this involve?MP: I don’t know what that science looks like. But one of the points I’m making is that it depends on the humanities. I found that I learned as much, if not more, about consciousness, from reading novels and poetry. There is a sense of the fullness and complexity of consciousness that you don’t get in any scientific account. I interviewed this stream-of-consciousness writer and I approached her as an expert on consciousness, and she is. So I think that dialogue is really important.I’m reading Ben Lerner’s new novel, Transcription. Just read the first page of this novel: it’s a man falling asleep on a train, going to conduct an interview, and there is the experience of being in the train, facing backwards, there’s the view outside, but there’s a reflection of himself through which he’s seeing outside. There’s the memory of dropping his kids off at school. All this is going on in one moment of consciousness. Scientists aren’t going anywhere near that. But I think it’s useful for them to think about. That’s where we’re trying to go: like, how does such a layered experience happen? You know, it also makes you wonder, could a computer ever do this? And it gives you some doubt.*AC: Before we get to computers, perhaps we could talk briefly about plants. How did you come to feel that they are sentient?MP: Well, it was a psychedelic experience, and it’s not unusual on psychedelics. In fact, there’ve been studies about how people become animists during psychedelic experience. Their belief in animism arises after a single psychedelic experience.You know, most scientists would say this is all a myth. But we have only 400 years of the age of enlightenment and science. Before that, we were animists, and if you go around the world, most indigenous cultures are still animists, and children are animists, by and large, until they go to school. So it could be that we live in this anomaly of not believing nature is conscious. And maybe psychedelics are teaching us something we’ve forgotten.As I said, I wanted to test this idea, and see whether there was conventional scientific evidence for it. And there’s fascinating work going on in a field that calls itself—in a rather cheeky way—plant neurobiology. These are people who fully realize there are no neurons in plants, but they’re trolling conventional botanists! And they’re doing experiments that are demonstrating that plants can learn and remember, which is kind of amazing: how do you store a memory without neurons? They’re finding plants that can solve problems, that can hear and see. In fact, they have 20 senses to our five or six. For example, a bean plant looking for something to twine, and given a pole within eight inches or so of it, knows where that pole is and will aim its spiraling reach at that pole. What is that about? Is it bouncing signals off of it?One of the spookiest things is the fact that the same anesthetics that put us out put plants out. You might think that plants are already out, but they’re not. They’re just slow. If you take a plant with a fast behavior, like a Venus flytrap, and give it an anesthetic, it will stop reacting. So you have to ask yourself, what is lost when the plant is anaesthetized? Some state of alertness, of awareness, of its environment, of reactivity. I’m not prepared to call that consciousness, but maybe it’s sentience—which is a simpler form of consciousness, and involves the ability to sense what’s going on in your environment and assess what’s good and bad for you and act appropriately. That may be a universal quality of life.AC: Let’s turn from plants to AI. You point out that LLMs are trained on the internet rather than direct interactions with reality. You put this really nicely when you say the internet is not the world so much as a shadow cast by the world. So LLMs are living in this kind of shadow world, or in Plato’s cave, as you put it. What’s the significance of this for AI consciousness and moral consideration? And, to recall the beginning of our conversation, if we’re stuck behind a veil or screen of consciousness, are we also stuck in a kind of shadow world?MP: I don’t think they’re the same shadow worlds because our world includes nature and other people. And even if it’s mediated in some ways... There is a reality out there, and we are in relation to it, through consciousness. There’s friction with it. What’s missing from the LLMs is that friction with the real world. There’s more to the world than human representation, which is what they’re dealing with. And that means that so far, AI is a cultural technology for combining thoughts we’ve already had. SUGGESTED VIEWING Cracking the code for thought With Roger Penrose, Sabrina Gonzalez Pasterski, Max Tegmark, Güneş Taylor Genuine creativity is more than collage. A lot of what AI does now is tantamount to collage, putting this with that and you know, that’s part of art, certainly. But there are also genuinely new ideas that come into the world that don’t come in through manipulating the representations we already have. So it remains to be seen whether AIs can be truly creative in that more radical sense.But my arguments against AI becoming conscious have to do with the fact that the idea of AI consciousness is based on this faulty metaphor that the brain is a computer. There are dimensions in which the brain is like a computer—it certainly does its share of computation. But computers have this sharp distinction between hardware and software, and brains don’t. In a brain, hardware and software are identical. Every memory is a physical change to the brain. Brains are not interchangeable in the way computers are. So this idea that you could take the consciousness out and somehow run it on another substrate, a silicon substrate, seems foolhardy.Anyway, it’s a more extended argument, and I may be wrong. And when we move to computers that aren’t based on silicon—neuromorphic computers and things like that—all bets may be off.AC: Regarding your point about LLMs being stuck in the world of our representations—the internet or whatever—and not being able to interact with reality, are these representations, the world of the internet, themselves part of reality? We’ve created the internet, but it’s still a real thing that exists. And so while the LLMs may be trapped within that part of reality, they’re nevertheless within reality and interacting with it and so on. So it’s not obvious that there’s a barrier there to them becoming conscious and being creative.MP: Yeah, I mean, if our consciousness is built out of human culture, which is what we’re talking about with all those representations. But I tend to think consciousness comes a bit more out of nature and friction with the natural world, but...AC: So there’s a fundamental divide between the natural world and human artefacts?MP: And we lose track of that, and especially people in this computer world. You know, the people who are creating these AI systems, my guess is they’ve been into video games since the age of three, and they didn’t go outside a lot. And their own contact with nature is somewhat limited. I could be wrong, it’d be a very interesting thing to ask, all the wizards of AI, whether they like to go fishing and hiking and do things like that. Or were they on computers from a very early age? I interviewed Blake Lemoine, the Google engineer who came to believe that LaMDA, the Google LLM out at the time, was conscious and deserved personhood. It was very clear that he didn’t see a distinction between this bubble in which he lived and the real world. And I think we’ve all been distanced from the natural world, and this is taking us even further away. But it’s still there, you know, and we still have bodies, and we’re still mortal, and we don’t live in a simulation.AC: I think that’s a great place to finish. Michael Pollan, thank you very much!
Temple researchers are building AI-powered health care ‘digital twins’ for people with ALS
A digital twin is a virtual representation of patients. Doctors plan to use the program to simulate treatments and therapies.
Red States’ Sound Science Laws Echo Trump Regulatory Overhaul
Republican-led states are following President Donald Trump’s lead and making it harder for their agencies to exceed federal environmental standards.
The science around GLP-1 drugs and cancer is suddenly getting a lot more interesting
Studies released in recent weeks are fueling optimism — and fresh questions — about GLP-1 drugs' potential role in cancer prevention and treatment.
A science powerhouse bets on genetic therapy to beat brain disorders
After spending two decades studying how the brain works, a huge team of scientists in Seattle is preparing to focus on treating brain diseases, including Alzheimer's and Parkinson's, using gene therapy.
Waiting times for healthcare in Europe: The worst countries ranked
Waiting times for treatment in some European countries can run for years. This has real consequences for patients, experts warn. Euronews Health takes a close look at waiting times across several categories.
Can You Delay Menopause? Experts Explain What's Actually Possible
Trendy treatments like rapamycin and red light therapy claim to delay menopause, but the science behind ovarian aging is complicated.
Records show Atlanta Beltline stabbing suspect received mental health services days before attack
Police records say the treatment came just 12 days before the deadly attack.
Trump retreated on his payout fund, but some Republicans want proof it’s dead
The Justice Department backed off a court fight over the nearly $1.8 billion fund for alleged victims of unfair prosecution. GOP senators say a pause isn’t a promise.
Hearing loss is bad for the whole body – but new treatments are coming
From dementia to heart attacks, hearing loss has been linked to a wide range of effects across the body, and the condition is on the rise. Fortunately, we're learning how best to safeguard this crucial sense and how we might be able to reverse the damage
How Science Works
The 2nd Weather and Climate Livestream is now underway. It is organized by a group of early-career researchers concerned about declining funding for the field and eager to demonstrate how weather and climate research makes a difference in our lives. Last year’s event was a great success, drawing terrific press coverage including a piece in the NY Times. This year features a strong lineup of talks aimed at a general audience — I highly recommend tuning in. Share I gave a talk yesterday about How Science Works in Three Steps. You can see the short presentation here (I’ve appended a transcript below): And please tune into the livestream here. It runs through tomorrow at 6 pm ET. Thanks for reading The Climate Brink! Subscribe for free to receive new posts and support our work. Subscribe Cleaned up transcript: Thank you, and thanks to everyone tuning in. I want to talk about something I think a lot of people don’t really understand: how science actually works. Arguments over any scientific topic — climate change, vaccines, you name it — revolve around competing claims. For climate change, the claims are: Is the Earth warming? Are humans to blame? What will the impacts be? Over the last 150 years, the scientific community has developed a remarkably robust method for sorting out which claims are true and which aren’t. That method is what I want to walk through. So how does science generate knowledge? If you ask a high schooler, they’ll give you the version they learned in ninth grade: an individual scientist forms a hypothesis, runs an experiment, and draws a conclusion. That’s more or less what happens at the individual level, though in practice it’s more iterative — you design, test, and refine all at once, landing on a slightly different idea each time until you reach a conclusion about whatever hypothesis you’ve ended up with. But this isn’t science. It’s only step one. Any individual scientist can make mistakes — scientists are human. Maybe there’s a bug in the code, maybe there’s an error in the experiment. Just because someone ran an experiment and reached a conclusion doesn’t mean it’s right, and scientists don’t treat a single result as settled truth. Step two is peer review, the first layer of quality control. The scientist writes up what they did and submits it to a journal, which sends the paper to other experts in the field. Those experts judge whether the methods are sound, whether it properly references prior work, and whether the conclusions actually follow from the data. Ask any scientist and they’ll tell you peer review is miserable — the comments come back brutal, often harsh, and you have to revise and resubmit, sometimes multiple times, before an editor finally accepts the paper. Peer review catches an immense amount of bad science, but it can’t catch all of it. Reviewers get sloppy or overworked, they miss obvious mistakes, and they can’t catch hidden errors — a bug in the code, a misread instrument. So a peer-reviewed paper making it into a journal doesn’t mean the paper is right. Nobody treats a single paper as the final word. That’s where step three comes in: the crucible of science. Important results get retested by the broader community. If you publish something interesting, it gets dissected. Sometimes people try to reproduce your work directly but more often they test its implications. If someone claims X is true, and that implies that Y is also true, then scientists will go check Y. If a claim survives this gauntlet long enough, it becomes accepted. That’s how we generate knowledge. Let me give an example: the ozone hole. In 1985 — and I doubt many people watching were around then, but I remember it well — Joe Farman and his colleagues published observations from Antarctica showing that a huge chunk of ozone was disappearing every year. This was shocking because most atmospheric chemists had expected ozone loss to occur at mid-latitudes and high altitudes, not over the South Pole. When scientists see something they don’t understand, they rush to explain it, and several competing hypotheses quickly appeared in the peer-reviewed literature. One pointed to chlorine chemistry from chlorofluorocarbons. A second blamed nitrogen chemistry, possibly driven by solar proton events — meaning the sun was responsible. A third argued it wasn’t chemistry at all but dynamics: winds were carrying naturally low-ozone air from the lower atmosphere up into the stratosphere. Then the community went to work testing which theory could survive the crucible. Aircraft flew into the ozone hole and found no nitrogen, ruling out the nitrogen theory. Measurements showed the air in the polar vortex was descending, not rising — which would bring high-ozone air down, eliminating the dynamics theory. Meanwhile, those same flights measured enormous amounts of chlorine, strongly correlated with exactly the regions where ozone was being destroyed. That became known as the “smoking gun” paper, and it established that chlorine chemistry was the cause. Through this process, a consensus emerged. And it’s worth being clear that this consensus is organic. There’s no vote, no poll, no meeting where it gets decided. Scientists go to conferences, talk to one another, and independently arrived at the same answer. It’s the ultimate free market of ideas. After the consensus was established, the peer-reviewed literature doesn’t even mention the rival theories — it simply takes chlorine chemistry as given. That’s what a consensus looks like. It doesn’t mean every single scientist agrees, but it does mean there’s no longer any legitimate debate. So where can you see what scientists actually think? It’s all in the peer-reviewed literature, which contains the entire historical record of the argument: the discovery, the competing theories, the debate, the testing, and finally the community coalescing around one answer. But there’s a lot of room for misrepresentation. You can dig up an old paper claiming the ozone hole was caused by dynamics and wave it around as if there still was a debate about the cause of the ozone hole — without mentioning that the idea was disproven long ago and that even its own authors no longer believe it. There’s a bigger problem, though: the peer-reviewed literature is written in a language I call “nerd.” It’s extremely hard to read — honestly, some of it is hard for me to follow. It takes graduate students years to work through the literature in a single field, so we can’t expect policymakers or ordinary people to do it. This is where scientific assessments come in. The most famous is the IPCC — the Intergovernmental Panel on Climate Change. The job of an assessment is to read and summarize the peer-reviewed literature, synthesizing what’s settled, what’s been disproven, and what remains genuinely debated. To ensure the assessments accurately summarize the peer-reviewed literature, assessments are written by large teams, which are far less prone to bias than individuals and which dilute the influence of any one scientist with an axe to grind. The teams are deliberately assembled to avoid stacking the deck, and the reports themselves go through multiple rounds of peer review. That rigorous process is exactly why you can trust them and why people consider the IPCC to be the gold standard of what we know about the climate system. An assessment produced through a different process may well not be credible. You can even watch the consensus evolve across assessments. Take the attribution of warming. The 1990 IPCC report said the observed warming was broadly consistent with model predictions but also comparable to natural variability — in other words, we don’t know whether humans are responsible. By 1995, it concluded that the balance of evidence suggested a discernible human influence — a sentence only a committee could write, and one that barely commits to anything. By 2001, most of the warming over the previous 50 years was judged “likely” due to greenhouse gases; by 2007, “very likely”; by 2013, “extremely likely.” The 2023 report says essentially the same as 2013 — there’s not much stronger language available. So, to wrap up: science is our ultimate tool for deciphering the universe — the most successful method we’ve ever developed for determining what’s true and what isn’t. Our understanding is written into the peer-reviewed literature, so if you want to know what scientists think, that’s where to look. And for those of us who don’t speak nerd, scientific assessments are the Rosetta Stone — they translate nerd into English. Let me open the floor to questions. Thank you.
Liverpool legend Sir Kenny Dalglish undergoing treatment for cancer
Sir Kenny Dalglish, one of the greatest and most important figures in Liverpool history, has revealed he is undergoing treatment for cancer. “As my inadvertent social media post has indicated, I am currently undergoing treatment for cancer,” Dalglish said in a statement. Liverpool said “the support, best wishes and love of everyone” at the club were with Dalglish and his family.
Deep Science Ventures and MDC partner to accelerate brain treatments
New collaboration aims to break barriers in brain‑targeted drug discovery
NC leader to encourage mental health treatment without commitment to psychiatric facility
North Carolinians who are suffering from mental illness are sometimes required by judicial officials to undergo treatment at a psychiatric facility — a process that could become more flexible if lawmakers take up a proposal expected Tuesday.
Health officials oppose US plan to treat Ebola-exposed Americans overseas
Healthcare officials in the U.S., including former Centers for Disease Control and Prevention officials, on Monday warned Congress against adopting a proposed policy to treat Americans exposed to Ebola in Kenya or countries in the European Union.
GLP-1 drugs like Ozempic show promise for more than weight loss. But what’s science vs hype?
Ozempic-style drugs have been flagged as possible treatments for cancer, dementia, endo, addiction and more. An expert explains what the evidence really says.
As Ebola Spreads, Scientists Race to Find Vaccines and Treatments
The Bundibugyo virus, a little known type, previously had caused just two small outbreaks. Now it’s at the center of a rapidly widening epidemic in Africa.
Ebola outbreak: How health workers are treating patients and staying safe in DR Congo
There are currently no approved drugs that target Bundibugyo - the species of Ebola responsible for this outbreak.
AP report: Trump is reconsidering $1.8 billion 'anti-weaponization' fund as DOJ temporarily pauses it
The potential retreat is a recognition of the legal setbacks the fund has encountered since it was announced two weeks ago.
Trump’s payout fund on shaky ground as Republicans push for retreat
The Justice Department said it would obey a court order pausing the nearly $1.8 billion fund, potentially signaling a broader pullback.
A famed folk-rock duo gets the musical treatment at Village Theatre
“We Ain’t Ever Gonna Break Up,” on stage at Village Theatre, loosely maps the tumultuous relationship of obvious analogs Simon & Garfunkel.
Baldur's Gate 2 remake reportedly in the works at Wizards of the Coast, with the first game "likely" getting the same treatment too
A rumour regarding Baldur's Gate's future says BG2 is being remade, maybe alongside the original, and co-lead designer Kevin Martens is involved.
Vanderbilt Health study explores GLP-1 therapies to improve asthma outcomes in patients with obesity
The study is still recruiting participants. It will conclude in 2026 and provide insight for further investigations into the role GLP-1 agonists may offer in treating respiratory illnesses and overall immune responses.
Ebola Scares In Brazil, Italy Prompt Fears Of Global Spread (Live Updates)
Protesters in Kenya are protesting plans by the U.S. to build a quarantine and treatment center at Laikipia Air Base.
The Back Pain Myths Patients Still Believe. And What Science Says Instead
Low back pain is one of the most common and misunderstood health problems in the world. Affecting 619 million people globally in 2020, it is now the single leading cause of disability worldwide, according to the World Health Organization (WHO). Yet despite how widespread it is, many people still make care decisions based on myths that can push them toward fear, inactivity, unnecessary treatment, and confusion before they understand what helps.
Confirmed Ebola cases in Congo reach 282 as survivors describe their recoveries
The outbreak remains focused in Congo's eastern Ituri province. Congo has reported over 1,000 suspected cases with the Bundibugyo virus, which has no approved treatment or vaccine.
Healing first: How Mendota Juvenile Treatment Center is succeeding
Mendota Juvenile Treatment Center in Madison provides care to some of Wisconsin's most troubled young people. It plans to expand.
Ebola recoveries bring signs of hope in DRC as suspected cases emerge outside Africa
Four nurses who were being treated for Ebola caused by the Bundibugyo strain of the virus have been discharged from a hospital in Bunia in the Democratic Republic of Congo (DRC) after recovering from the disease, the World Health Organization (WHO) said on Sunday.
Explore the engine accelerating new cancer treatments at UT San Antonio
See how the university is spurring the path from discovery to care, expanding access to advanced cancer treatments and clinical trials.
📸 RC Lens unveil their new home shirt 🟡🔴
A major change!The breakout team of this 2025-2026 Ligue 1 season is treating fans this Monday morning!RC Lens has just unveiled its home kit for next season.A jersey designed by Adidas, not Puma! The...
Role of Physical Activity in Obesity Treatment and Cardiometabolic Health
Obesity affects 42% of adults in the United States and is strongly associated with major cardiovascular disease risk factors, including high blood pressure, abnormal cholesterol levels, and insulin resistance, making effective obesity treatment a critical public health priority.
Experimental drug shows promise against deadly pancreatic cancer
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer.
WHO chief reports 5 Ebola recoveries as new treatment center opens in Congo
Five patients have recovered from a rare type of Ebola virus, the head of the World Health Organization said Sunday during a visit to Bunia in eastern Congo.
Community unites for Fenway Health’s Strides for Action 5K in Boston
Hundreds of advocates and community leaders came together Sunday morning to support HIV prevention and treatment, LGBTQIA+ health services, research, and advocacy.
Why Trump reversed course to fast-track psychedelic drugs for mental healthcare
President Donald Trump is trying to fast-track research into psychedelics as treatments, creating new opportunities and risks.
‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long
The highly anticipated results of a clinical trial for the pill, daraxonrasib, have been released, giving doctors hope for treating the stubbornly lethal disease.
WHO chief hails 5 Ebola recoveries as a new treatment center opens in eastern Congo
The World Health Organization reports that five patients have recovered from a rare type of Ebola in eastern Congo.
WHO chief hails 5 Ebola recoveries as a new treatment center opens in eastern Congo
The World Health Organization reports that five patients have recovered from a rare type of Ebola in eastern Congo.
How Nigeria’s ‘algorithmic apothecary’ fuels a surge in risky herbal cures
Unverified herbal remedies promoted on social media are driving rising health risks and delayed treatment in Nigeria.
Contraception For Teens: Let's Talk About It
By Mahvash Madni, MD, FAAP HealthDay ReporterSATURDAY, May 30, 2026 (HealthDay News) — Contraception is not just about preventing an unwanted pregnancy. Experts say it’s also an important part of adolescent health care, helping regulate menstrual cycles, manage painful symptoms and treat some hormone-related conditions. Understanding the ...
Governor Gianforte Announces Montana Secures Federal Funding to Establish Behavioral Health Clinics
HELENA, Mont. – Governor Greg Gianforte and Department of Public Health and Human Services (DPHHS) Director Charlie Brereton today announced the Trump administration selected Montana as one of ten states to receive federal funding to expand access to mental health and substance use disorder treatment across the state.
HHS Unveils Sweeping Plan to Combat Lyme Disease and Advance Treatment
U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. today announced a series of major initiatives to strengthen the nation’s response to Lyme disease and other tick-borne illnesses.